US3647877A - Aminopropionanilides - Google Patents

Aminopropionanilides Download PDF

Info

Publication number
US3647877A
US3647877A US28120A US3647877DA US3647877A US 3647877 A US3647877 A US 3647877A US 28120 A US28120 A US 28120A US 3647877D A US3647877D A US 3647877DA US 3647877 A US3647877 A US 3647877A
Authority
US
United States
Prior art keywords
chloro
propionanilide
methoxy
diethylamino
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US28120A
Inventor
Abraham Weber
Jacques Jean Frossard
Daniel Bouzard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mead Johnson and Co LLC
Original Assignee
Mead Johnson and Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mead Johnson and Co LLC filed Critical Mead Johnson and Co LLC
Application granted granted Critical
Publication of US3647877A publication Critical patent/US3647877A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms

Definitions

  • R stands for hydrogen and lower alkyl of from 1 to 3 carbon atoms inclusive.
  • Lower alkyl is comprised of straight or branched carbon chains having from 1 to 3 carbon atoms inclusive such as, methyl, ethyl, propyl, and isopropyl.
  • the positions of the aromatic ring in Formula I are numbered.
  • the nitration is carried out by adding fuming nitric acid to a glacial acetic acid solution of 5 chloro 2 methoxy-2-bromopropi0nanilide (III).
  • the bromopropionanilide (1V) treated with an excess of diethylamine in ethanol as a solvent furnishes 5'-chloro-2-methoxy 4' nitro-(2-diethylamino)propionanilide (V) which is catalytically reduced in an alcoholic solvent to 4'-amino 5 chloro 2 methoxy-(Z-diethylamino)propionanilide (VI).
  • Alcoholic solvents such as methanol, ethanol and isopropanol are particularly useful.
  • the reduction is preferably carried out employing platinum oxide or Raney nickel as the catalyst. Alternatively the reduction may be carried out with iron powder and hydrochloric acid in ethanolic solution.
  • Formula I compounds of the present invention wherein R is lower alkyl are prepared by acylation of 4'-amino-5'- chloro-2-methoxy (Z-diethylamino)propionanilide (V1) with alkanoyl halides or alkanoic acid anhydrides in an inert reaction solvent such as acetone, acetonitrile, dioxane, benzene, chloroform and the like.
  • reaction of 4-amino 5' chloro-2'-methoxy-(2-diethylamino)propionanilide (VI) with an alkanoyl halide such as propionyl chloride in acetone provides 5'-chloro-2'- methoxy-4'-propionamido (Z-diethylamino)propionanilide while reaction of an alkanoic acid anhydride such as acetic anhydride with VI yields 5'-chloro-2-methoxy-4'- acetamido- Z-diethylamino propionanilide.
  • the compound of Formula I wherein R is hydrogen, 5- chloro 2' methoxy 4 formainido-(2-diethylamino) propionanilide, is obtained by formylation of 4-amino- 5-chloro 2' methoxy-(Z-diethylamino) propionanilide with formic acid.
  • the compounds of Formula I are basic compounds and as free bases are practically insoluble in water although they are readily soluble in organic solvents. Acid addition salts of Formula I are generally water soluble.
  • Non-toxic pharmaceutically acceptable acid addition salts are converted to the non-toxic pharmaceutically acceptable acid addition salts by treating an acetone solution of the free base with gaseous or ethanolic hydrogen chloride.
  • Other non-toxic pharmaceutically acceptable acid addition salts can also be prepared by treating the free base of the compounds of Formula I with other suitable organic or inorganic acids.
  • acids for this purpose include hydrobromic, sulfuric, phosphoric, nitric, benzoic, methylsulfonic, p-tolylsulfonic, benzenesulfonic, naphthylene sulfonic, salicylic, glycolic, acetic, maleic, succinic, tartaric, stearic, palmitic, citric, glutaric, lactic, and so on.
  • the compounds of the present invention defined by Formula I and their salts possess useful pharmacological activity in mammals. These compounds, in particular, possess central nervous system depressant (including tranquilizing, sedative and hypnotic) and anti-spasmodic activity. More particularly, systemic administration of the compounds of the present invention to mammals produces a hypnotic effect therein.
  • intravenous administration of 2-methoxy-4'-acetamido-5-chloro(2-diethylamino)propionanilide to a mouse at a dose of milligrams per kilogram of body weight produces an hypnotic effect lasting about 17 minutes.
  • This same compound administered intraperitoneally to the mouse at a dose of 250 mg./kg. of body weight produces an hypnotic effect lasting about 41 minutes whereas a dose of 500 mg./kg. administered orally results in an hypnotic effect lasting about 39 minutes.
  • systemic administration of the compounds of Formula I to mammals between dosages ranging from about 2.0 to about 750 rug/kg. of body weight of the mammal produces significant depression of the central 3 nervous system to induce an hypnotic effect.
  • a single or multiple dose that is equivalent to a range from about 125 mg. to about 1000 mg. per day per mammal is preferred.
  • the compounds of the present invention are relatively non-toxic at the dosage necessary to produce a useful pharmacological activity.
  • Intraperitoneal LD values in the mouse for the compounds of the present invention are in excess of 400 mg./kg. body weight.
  • Representative of the toxicity of the compounds of the present invention is 2'-methoxy-4'-acetamido-5-chloro-(2 diethylamino)propionanilide which has, in the mouse, an intraperitoneal LD value of 687 mg./kg.
  • this compound has LD values of 580 mg./kg. when administered intraperitoneally and 1320 mg./kg. when administered orally.
  • the compounds of the present invention are well tolerated when chronically administered.
  • the compounds of Formula I can be administered to mammals in the form of free bases or in the form of one of their non-toxic pharmaceutically acceptable addition salts of Formula I compounds.
  • the compounds of Formula I can be compounded and formulated into pharmaceutical compositions of unit dosage forms suitable for systemic administration with organic or inorganic solid materials or liquids such as corn starch, lactose, Water, sesame seed oil, peanut oil, propylene glycol and so on.
  • Pharmaceutical compositions considered within the scope of this invention may take the form of tablets, powder, granules, capsules, suspensions, solutions, suppositories, elixirs, ointments and the like.
  • pharmaceutical unit dosage forms comprise a significant quantity of a pharmaceutical carrier hereinabove described and from about 2-750 milligrams of the compounds of Formula I.
  • (C) 4 amino-5'-chloro-2'-methoxy- (2-diethylamino)- propionanilide The 5'-chloro-2'-methoxy-4'-nitro-(2-diethylamino)propionanilide intermediate (30 g., 0.1 mole) is catalytically hydrogenated in 500 ml. of methanol at room temperature employing 0.5 g. of platinum oxide (PtO -H O) catalyst. After the calculated amount of hydrogen (0.3 mole) has been absorbed, the mixture is filtered and the filtrate concentrated. The residue crystallized from ethanol provides analytically pure 4-amino-5'- chloro 2' methoxy-(Z-diethylamino)propionanilide, a white solid with a melting point of 156 C.
  • PtO -H O platinum oxide
  • the hydrochloric salt of 5'-chloro-2'-methoxypropionamido-(Z-diethylamino)propionanilide is prepared by dissolving the base in acetone and acidifying with hydrogen chloride. The hydrochloride melts at 200 C. with decomposition.
  • EXAMPLE 3 5 '-chloro-2-methoxy-4- Z-methylpropionamido) (2- diethylamine)propionanilide
  • the procedure of Example 2 is repeated substituting isobutyryl chloride (Z-methylpropionyl chloride) for propionyl chloride.
  • the product is purified by crystallization from cyclohexane and has a melting point of 99 C.
  • EXAMPLE 4 5'-chloro-2'-methoxy-4-butyrylamido-( Z-diethylamino) propionanilide
  • the procedure of Example 2 is repeated employing nbutyryl chloride in lieu of propionyl chloride.
  • the product can be crystallized from isopropyl ether and has a melting point of 74 C.
  • EXAMPLE 5 5'-chloro-2'-metl1oxy- -formamido-(Z-diethylamino) propionanilide
  • a mixture of 4-amino-5'-chloro-2'-methoxy-(Z-diethylamino)propionanilide (3.0 g., 0.01 mole) and 3 ml. of formic acid (98100%) is refluxed for 4 hrs., cooled and dissolved in water.
  • the solution is made basic by the addition of 2 N sodium hydroxide solution providing a precipitate which is taken up in ether. After washing the ethereal solution with water, drying over magnesium sul fate and evaporating there is obtained 2.8 g. of a residue melting at 100-102" C. Crystallization of the residue from 2-propanol affords 5 chloro-2-methoxy-4-formamido-Z-(diethylamino)propionanilide having a melting point of 104 C.
  • the foregoing materials are blended in a twin-shell blender and then granulated and then pressed into tablets weighing 250 mg. each. Each tablet contains 125 milligrams of active ingredient.
  • EXAMPLE 7 Solution for parenteral injection
  • the propionanilides of Formula I are formulated for parenteral administration according to the following example.
  • a sterile solution is prepared by dissolving 22 g. of 5'-chloro-2'-methoxy-4'-acetamido-(2 diethylamino) propionanilide hydrochloride in 2 liters of water for injection, USP.
  • the solution is adjusted to pH 4.2 with 0.1 N-sodium hydroxide and then sterilized by passage through a bacteriological filter.
  • Ten milliliter glass ampules are aseptically filled with a sufficient amount (about 5 ml.) of the solution to provide a dose of 50 mg. of active ingredient per ampule,
  • R is hydrogen or lower alkyl from 1 to 3 carbon atoms inclusive, and the non-toxic pharmaceutically acceptable salts thereof.
  • a compound of the group defined in claim 1 which is 5' chloro-2-methoxy-4'-acetamido (Z-diethylamino) propionanilide.
  • a compound of the group defined in claim 1 which is 5' chloro-2'-methoxy-4'-acetamido-(2-diethylamino)- propionanilide hydrochloride.
  • a compound of the group defined in claim 1 which is 5 chloro-2'-methoxy 4 propionamido-(Z-diethylamino) propionanilide.
  • a compound of the group defined in claim 1 which is 5' chloro-2'-methoxy 4 propionamido-(2-diethy1- amino)propionanilide hydrochloride.

Abstract

THIS INVENTION RELATES TO AMINOPROPIONANILIDES, WHICH ARE PREPARED BY ACYLATION OF 4''-AMINO-5''-CHLORO-2''-METHOXY-(2-DIETHYLAMINO)PROPIONANILIDE WITH (LOWER) ALKANOYL HALIDES OR (LOWER) ALKANOIC ACID ANHYDRIDES. THE DIETHYLAMINO PROPIONANILIDE PRODUCTS ARE PHARMACOLOGICALLY ACTIVE IN MAMMALS AND WHEN ADMINISTERED THERETO IN EFFECTIVE DOSES PRODUCED DEPRESSION OF THE CENTRAL NERVOUS SYSTEM WITH RESULTING HYPNOSIS. DIETHYLAMINOPROPIONANILIDES WHICH ARE PARTICULARLY USEFUL AS HYPNOTIC AGENTS ARE 2''METHOXY-4''-ACETAMIDO-5''-CHLORO-(2-DIETHYLAMINO)PROPIONANILIDE AND 2''-METHOXY-4''-PROPIONAMIDO-5''-CHLORO(2-DIETHYLAMINO)PROPIONANILIDE.

Description

United States Patent 3,647,877 AMINOPROPIONANILIDES Abraham Weber, Paris, Jacques Jean Frossard, Champigny, and Daniel Bouzard, Franconville, France, assignors to Mead Johnson & Company, Evansville, Ind. No Drawing. Filed Apr. 13, 1970, Ser. No. 28,120 Int. Cl. C07c 103/44 U.S. Cl. 260--562 N Claims ABSTRACT OF THE DISCLOSURE SUMMARY OF THE INVENTION This invention relates to aminopropionanilides represented by Formula I and acid addition salts thereof.
Formula I In the above formula, R stands for hydrogen and lower alkyl of from 1 to 3 carbon atoms inclusive. Lower alkyl is comprised of straight or branched carbon chains having from 1 to 3 carbon atoms inclusive such as, methyl, ethyl, propyl, and isopropyl. As an aid to nomenclature, the positions of the aromatic ring in Formula I are numbered.
The process for the preparation of the aminopropionanilides of Formula I is schematically represented by the following formulas:
Condensation of 5-chloro-2-methoxyaniline (II) with 2- bromopropionyl chloride provides 5'-chloro-2'-methoxy-2- bromopropionanilide (HI). Hydrogen chloride is evolved during the condensation which is preferably carried out in benzene solution employing an excess of 2-bromopropionyl 3,647,877 Patented Mar. 7, 1972 chloride with respect to 5-chloro-Z-methoxyaniline. Nitration of (III) yields 5'-chloro-2'-methoxy-4'-nitro-2-bromopropionanilide (IV). Preferably, the nitration is carried out by adding fuming nitric acid to a glacial acetic acid solution of 5 chloro 2 methoxy-2-bromopropi0nanilide (III). The bromopropionanilide (1V) treated with an excess of diethylamine in ethanol as a solvent furnishes 5'-chloro-2-methoxy 4' nitro-(2-diethylamino)propionanilide (V) which is catalytically reduced in an alcoholic solvent to 4'-amino 5 chloro 2 methoxy-(Z-diethylamino)propionanilide (VI). Alcoholic solvents such as methanol, ethanol and isopropanol are particularly useful. The reduction is preferably carried out employing platinum oxide or Raney nickel as the catalyst. Alternatively the reduction may be carried out with iron powder and hydrochloric acid in ethanolic solution.
Formula I compounds of the present invention wherein R is lower alkyl are prepared by acylation of 4'-amino-5'- chloro-2-methoxy (Z-diethylamino)propionanilide (V1) with alkanoyl halides or alkanoic acid anhydrides in an inert reaction solvent such as acetone, acetonitrile, dioxane, benzene, chloroform and the like. For example, reaction of 4-amino 5' chloro-2'-methoxy-(2-diethylamino)propionanilide (VI) with an alkanoyl halide such as propionyl chloride in acetone provides 5'-chloro-2'- methoxy-4'-propionamido (Z-diethylamino)propionanilide while reaction of an alkanoic acid anhydride such as acetic anhydride with VI yields 5'-chloro-2-methoxy-4'- acetamido- Z-diethylamino propionanilide.
The compound of Formula I wherein R is hydrogen, 5- chloro 2' methoxy 4 formainido-(2-diethylamino) propionanilide, is obtained by formylation of 4-amino- 5-chloro 2' methoxy-(Z-diethylamino) propionanilide with formic acid.
The compounds of Formula I are basic compounds and as free bases are practically insoluble in water although they are readily soluble in organic solvents. Acid addition salts of Formula I are generally water soluble.
Compounds of the present invention represented by Formula I are converted to the non-toxic pharmaceutically acceptable acid addition salts by treating an acetone solution of the free base with gaseous or ethanolic hydrogen chloride. Other non-toxic pharmaceutically acceptable acid addition salts can also be prepared by treating the free base of the compounds of Formula I with other suitable organic or inorganic acids. Exemplary of acids for this purpose include hydrobromic, sulfuric, phosphoric, nitric, benzoic, methylsulfonic, p-tolylsulfonic, benzenesulfonic, naphthylene sulfonic, salicylic, glycolic, acetic, maleic, succinic, tartaric, stearic, palmitic, citric, glutaric, lactic, and so on.
The compounds of the present invention defined by Formula I and their salts possess useful pharmacological activity in mammals. These compounds, in particular, possess central nervous system depressant (including tranquilizing, sedative and hypnotic) and anti-spasmodic activity. More particularly, systemic administration of the compounds of the present invention to mammals produces a hypnotic effect therein. For example, intravenous administration of 2-methoxy-4'-acetamido-5-chloro(2-diethylamino)propionanilide to a mouse at a dose of milligrams per kilogram of body weight produces an hypnotic effect lasting about 17 minutes. This same compound administered intraperitoneally to the mouse at a dose of 250 mg./kg. of body weight produces an hypnotic effect lasting about 41 minutes whereas a dose of 500 mg./kg. administered orally results in an hypnotic effect lasting about 39 minutes.
In general, systemic administration of the compounds of Formula I to mammals between dosages ranging from about 2.0 to about 750 rug/kg. of body weight of the mammal produces significant depression of the central 3 nervous system to induce an hypnotic effect. For larger mammals of about 70 kg. average body weight, a single or multiple dose that is equivalent to a range from about 125 mg. to about 1000 mg. per day per mammal is preferred.
The compounds of the present invention are relatively non-toxic at the dosage necessary to produce a useful pharmacological activity. Intraperitoneal LD values in the mouse for the compounds of the present invention are in excess of 400 mg./kg. body weight. Representative of the toxicity of the compounds of the present invention is 2'-methoxy-4'-acetamido-5-chloro-(2 diethylamino)propionanilide which has, in the mouse, an intraperitoneal LD value of 687 mg./kg. In the rat this compound has LD values of 580 mg./kg. when administered intraperitoneally and 1320 mg./kg. when administered orally. The compounds of the present invention are well tolerated when chronically administered.
The compounds of Formula I can be administered to mammals in the form of free bases or in the form of one of their non-toxic pharmaceutically acceptable addition salts of Formula I compounds. In either form the compounds of Formula I can be compounded and formulated into pharmaceutical compositions of unit dosage forms suitable for systemic administration with organic or inorganic solid materials or liquids such as corn starch, lactose, Water, sesame seed oil, peanut oil, propylene glycol and so on. Pharmaceutical compositions considered within the scope of this invention may take the form of tablets, powder, granules, capsules, suspensions, solutions, suppositories, elixirs, ointments and the like. Preferably, pharmaceutical unit dosage forms comprise a significant quantity of a pharmaceutical carrier hereinabove described and from about 2-750 milligrams of the compounds of Formula I.
The following examples are intended to illustrate and are not to be construed as limiting the scope of the present invention.
DESCRIPTION OF THE SPECIFIC EMBODIMENTS EXAMPLE 1 5'-chloro-2'-methoxy-4-acetamido- (Z-diethylamino) propionanilide (A) 5-chloro-2-methoxy-4'-nitro 2 bromopropionanilide: 5 -chloro-2-methoxyaniline reacted with 2-bromopropionyl chloride in benzene provides 5'-chloro-2-methoxy-2-bromopropionanilide, M.P. 133 C. This material is nitrated in the following manner. A stirred suspension of 290 g. of 5-chloro-2-methoxy-2-bromopropionanilide in 1.8 liters of glacial acetic acid is treated over a period of 1 hours with 220 ml. of fuming nitric acid (d.=1.52) at a temperature of 35 C. The mixture is stirred for one hour at room temperature and then poured into 6 liters of cold water. The propionanilide crystallizes and is col lected and dried, yield 323 g., M.P. 121 C.
(B) 5'-chloro2'-methoxy 4' nitro-(2-diethylamino)- propionanilide: A stirred solution of 914 g. (2.7 mole) of -methoxy-4'-nitro-2'-bromopropionanilide in 3 liters of ethanol is treated slowly with 1 liter of diethylamine (706 g., 9.7 mole) while maintaining a temperature of 35 C. The mixture is refluxed for 4 hours, cooled and permitted to stand overnight. A yellowish solid precipitates which is collected and dried, yield 750 g., M.P. 143 C.
(C) 4 amino-5'-chloro-2'-methoxy- (2-diethylamino)- propionanilide: The 5'-chloro-2'-methoxy-4'-nitro-(2-diethylamino)propionanilide intermediate (30 g., 0.1 mole) is catalytically hydrogenated in 500 ml. of methanol at room temperature employing 0.5 g. of platinum oxide (PtO -H O) catalyst. After the calculated amount of hydrogen (0.3 mole) has been absorbed, the mixture is filtered and the filtrate concentrated. The residue crystallized from ethanol provides analytically pure 4-amino-5'- chloro 2' methoxy-(Z-diethylamino)propionanilide, a white solid with a melting point of 156 C.
AnaZysis.Calcd. for C H ClN O (percent): C, 56.08; H, 7.39; N, 14.01. Found (percent): C, 56.09; H, 7.36; N, 14.22.
(D) Acetic anhydride (10.2 g., 0.1 mole) is slowly added to 4'-amino-5-chloro-2-methoxy-(Z-diethylamino) propionanilide (30 g., 0.1 mole) in 300 ml. of benzene. The mixture stirred and refluxed for 2 hrs. and the henzene solvent then removed by evaporation provides a residue which is taken up dilute hydrochloric acid. The acidic solution is basified with concentrated ammonium hydroxide and then extracted with ether. After drying, the ethereal solution is concentrated and the residual base crystallized from cyclohexane to provide analytically pure 5 chloro-2-methoxy 4 acetamido-(Z-diethylamino) propionanilide.
Analysis.Calcd. for C H C1N O (percent): C, 56.21; H, 7.07; N, 12.29. Found (percent): C, 56.49; H, 7.76; N, 12.39.
EXAMPLE 2 5 -chloro-2-methoxy-4'-propionamido- 2-diethylamino) propionanilide Propionyl chloride (18 ml., 19.2 g., 0.28 mole) in 150 ml. of acetone is added rapidly to 4-amino-5'-chloro-2- methoxy-(Z-diethylamino)propionanilide (51 g., 0.17 mole) in 400 ml. of acetone with stirring. After the addition is completed, the mixture is refluxed for 2 hrs., and the solvent is evaporated providing a residue which is taken up in dilute hydrochloric acid. The hydrochloric acid solution is made basic with ammonia and then extracted with ether. The ethereal extract is washed with water, dried and concentrated to a small volume. On refrigeration there is obtained 47 g. of product, M.P. C.
Analysis.Calcd. for C H ClN O (percent): C, 57.37; H, 7.36; N, 11.80. Found (percent): C, 56.40; H, 7.25; N, 11.70.
The hydrochloric salt of 5'-chloro-2'-methoxypropionamido-(Z-diethylamino)propionanilide is prepared by dissolving the base in acetone and acidifying with hydrogen chloride. The hydrochloride melts at 200 C. with decomposition.
EXAMPLE 3 5 '-chloro-2-methoxy-4- Z-methylpropionamido) (2- diethylamine)propionanilide The procedure of Example 2 is repeated substituting isobutyryl chloride (Z-methylpropionyl chloride) for propionyl chloride. The product is purified by crystallization from cyclohexane and has a melting point of 99 C.
Analysis.-Calcd. for C H ClN O (percent): C, 58.45; H, 7.63; N, 11.36. Found (percent): C, 58.62; H, 7.75; N, 11.60.
EXAMPLE 4 5'-chloro-2'-methoxy-4-butyrylamido-( Z-diethylamino) propionanilide The procedure of Example 2 is repeated employing nbutyryl chloride in lieu of propionyl chloride. The product can be crystallized from isopropyl ether and has a melting point of 74 C.
Analysis.Calcd. for C H ClN O (percent): C, 58.45; H, 7.63; N, 11.36. Found (percent): C, 58.21; H, 7.70; N, 11.64.
EXAMPLE 5 5'-chloro-2'-metl1oxy- -formamido-(Z-diethylamino) propionanilide A mixture of 4-amino-5'-chloro-2'-methoxy-(Z-diethylamino)propionanilide (3.0 g., 0.01 mole) and 3 ml. of formic acid (98100%) is refluxed for 4 hrs., cooled and dissolved in water. The solution is made basic by the addition of 2 N sodium hydroxide solution providing a precipitate which is taken up in ether. After washing the ethereal solution with water, drying over magnesium sul fate and evaporating there is obtained 2.8 g. of a residue melting at 100-102" C. Crystallization of the residue from 2-propanol affords 5 chloro-2-methoxy-4-formamido-Z-(diethylamino)propionanilide having a melting point of 104 C.
Analysis.-Calcd. for C H ClN O (percent): N, 12.82; Cl, 10.81. Found (percent): N, 12.71; Cl. 10.12.
EXAMPLE 6 Tablets The propionanilides of Formula I are compounded into tablets according to the following example.
Material: Amount, g.
5' chloro-2'-methoxy-4'-acetamido-(2-diethylamino)propionanilide 125.0 Magnesium stearate 1.3 Corn starch 12.4 Corn starch pregel-atinized 1.3 Lactose 110.0
The foregoing materials are blended in a twin-shell blender and then granulated and then pressed into tablets weighing 250 mg. each. Each tablet contains 125 milligrams of active ingredient.
EXAMPLE 7 Solution for parenteral injection The propionanilides of Formula I are formulated for parenteral administration according to the following example. A sterile solution is prepared by dissolving 22 g. of 5'-chloro-2'-methoxy-4'-acetamido-(2 diethylamino) propionanilide hydrochloride in 2 liters of water for injection, USP. The solution is adjusted to pH 4.2 with 0.1 N-sodium hydroxide and then sterilized by passage through a bacteriological filter. Ten milliliter glass ampules are aseptically filled with a sufficient amount (about 5 ml.) of the solution to provide a dose of 50 mg. of active ingredient per ampule,
While several specific embodiments are described in the foregoing, it will be appreciated that other modifications may be made without departing from the spirit and scope of the appended claims.
What is claimed is:
1. A compound selected from the group consisting of aminopropionanilides having the formula:
0 c1 0 11 EN one 017 0 ima wherein R is hydrogen or lower alkyl from 1 to 3 carbon atoms inclusive, and the non-toxic pharmaceutically acceptable salts thereof.
2. A compound of the group defined in claim 1 which is 5' chloro-2-methoxy-4'-acetamido (Z-diethylamino) propionanilide.
3. A compound of the group defined in claim 1 which is 5' chloro-2'-methoxy-4'-acetamido-(2-diethylamino)- propionanilide hydrochloride.
4. A compound of the group defined in claim 1 which is 5 chloro-2'-methoxy 4 propionamido-(Z-diethylamino) propionanilide.
5. A compound of the group defined in claim 1 which is 5' chloro-2'-methoxy 4 propionamido-(2-diethy1- amino)propionanilide hydrochloride.
References Cited UNITED STATES PATENTS 3,424,767 1/ 1969 Burdeska et al. 260562 HENRY R. JILES, Primary Examiner H. I. MOATZ, Assistant Examiner U.S. Cl. X.R.
US28120A 1970-04-13 1970-04-13 Aminopropionanilides Expired - Lifetime US3647877A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2812070A 1970-04-13 1970-04-13

Publications (1)

Publication Number Publication Date
US3647877A true US3647877A (en) 1972-03-07

Family

ID=21841681

Family Applications (1)

Application Number Title Priority Date Filing Date
US28120A Expired - Lifetime US3647877A (en) 1970-04-13 1970-04-13 Aminopropionanilides

Country Status (9)

Country Link
US (1) US3647877A (en)
JP (1) JPS501259B1 (en)
BE (1) BE765397A (en)
CH (1) CH547775A (en)
DE (1) DE2116160A1 (en)
FR (1) FR2092039B1 (en)
GB (1) GB1334125A (en)
NL (1) NL7104767A (en)
ZA (1) ZA712180B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331816A (en) * 1977-04-22 1982-05-25 Beecham Group Limited Aniline analeptics
US5331012A (en) * 1990-07-30 1994-07-19 Riddick Kenneth B Topical pharmaceutical preparation for fever blisters and other viral infections and method of use

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52135981U (en) * 1976-04-09 1977-10-15
JPS5596309U (en) * 1978-12-26 1980-07-04

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331816A (en) * 1977-04-22 1982-05-25 Beecham Group Limited Aniline analeptics
US5331012A (en) * 1990-07-30 1994-07-19 Riddick Kenneth B Topical pharmaceutical preparation for fever blisters and other viral infections and method of use

Also Published As

Publication number Publication date
CH547775A (en) 1974-04-11
ZA712180B (en) 1971-12-29
FR2092039B1 (en) 1974-08-30
BE765397A (en) 1971-10-06
GB1334125A (en) 1973-10-17
JPS501259B1 (en) 1975-01-16
NL7104767A (en) 1971-10-15
DE2116160A1 (en) 1971-10-28
FR2092039A1 (en) 1972-01-21

Similar Documents

Publication Publication Date Title
US4148897A (en) 1,2-Dihydronaphthalene derivatives and pharmaceutical composition
US3639477A (en) Novel propoxyguanidine compounds and means of producing the same
US3389139A (en) 6-homopiperazino and piperazinomorphanthridines
NZ197582A (en) Dextrorotatory trans-4a,9b-5phenyl-2,3,4,4a,5,9b-hexahydro-1h-pyrido(4,3-b) indoles
CH500194A (en) Anorexigenic benzazepins
US3759927A (en) B-benzofurylmethyl-1,3,8-triazaspiro(4,5)decanes
US4086353A (en) Certain azolinylamino (azolidinylimino) indazoles
US3647877A (en) Aminopropionanilides
US3024248A (en) Organic sulfur compounds and method for producing same
US3383382A (en) N-amino-iminodibenzyl
US3732243A (en) 2-(p-bromophenyl)-9-dimethyl-amino-propyl-9h-imidazo(1,2-a)benzimidazole
US3426017A (en) Sulfonylurea compounds
US3882119A (en) Tetracyclic substituted phthalazine compounds
US4235921A (en) Treating muscular spasms and convulsions with 3-azabicyclo[3.1.0]hexanes
US3775479A (en) Amine compounds
US3483209A (en) Aralkylamines
Elslager et al. Synthetic Schistosomicides. VI. 4-Substituted 1-(Dialkylaminoalkylamino) naphthalenes1
US3725419A (en) Quinuclidylalkyl esters
US4013679A (en) Substituted 6,7-dihydro [1,7-ab](1) benzazepine compounds
US2985653A (en) New piperazinyl-alkyl-phenthiazines and their preparation
JPS5825678B2 (en) Oxazole powder
US3457271A (en) 11-lower alkyl-hexahydro-1-benzazepino (3,2,1-h,i)pyrido(4,3-b)indole
US3687936A (en) 11-AMINOALIPHATIC-5:10-METHANODIBENZO {8 a:d{9 {0 {8 1:4{9 {0 CYCLOHEPTADIENES AND THE SALTS THEREOF
US3629433A (en) Antidepressant compositions of cycloalkano(c)pyrazole ethers
US3911017A (en) 5-Aminomethyl-5H-dibenzo{8 a,d{9 cycloheptenes